{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:30:15Z","timestamp":1792276215909,"version":"4.4.0"},"reference-count":108,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:00:00Z","timestamp":1630540800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.cmi.2020.04.019","type":"journal-article","created":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T11:39:25Z","timestamp":1588073965000},"page":"1161-1170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Interactions between antiretroviral therapy and complementary and alternative medicine: a narrative review"],"prefix":"10.1016","volume":"26","author":[{"given":"C.","family":"Bordes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Leguelinel-Blache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-P.","family":"Lavigne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-M.","family":"Mauboussin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Laureillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Faure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Rouanet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Loubet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2020.04.019_bib1","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1089\/apc.2013.0175","article-title":"A\u00a0Review of the use of complementary and alternative medicine and HIV: issues for patient care","volume":"27","author":"Lorenc","year":"2013","journal-title":"AIDS Patient Care STDs"},{"key":"10.1016\/j.cmi.2020.04.019_bib2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1742-6405-10-12","article-title":"Self-care practices and experiences of people living with HIV not receiving antiretroviral therapy in an urban community of Lusaka, Zambia: implications for HIV treatment programmes","volume":"10","author":"Musheke","year":"2013","journal-title":"AIDS Res Ther"},{"key":"10.1016\/j.cmi.2020.04.019_bib3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/00126334-200306010-00007","article-title":"Complementary and alternative medicine use and substitution for conventional therapy by HIV-infected patients","volume":"33","author":"Hsiao","year":"2003","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.cmi.2020.04.019_bib4","first-page":"1686","article-title":"Herbal product use in non-HIV and HIV-positive Hispanic patients","volume":"97","author":"Rivera","year":"2005","journal-title":"J\u00a0Natl Med Assoc"},{"key":"10.1016\/j.cmi.2020.04.019_bib5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1089\/107555303321222955","article-title":"Use of complementary and alternative therapies by patients with human immunodeficiency virus disease in the era of highly active antiretroviral therapy","volume":"9","author":"Bica","year":"2003","journal-title":"J\u00a0Altern Complement Med"},{"key":"10.1016\/j.cmi.2020.04.019_bib6","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1089\/108729103321619764","article-title":"Use of complementary and alternative medicine by HIV-infected outpatients in Ontario, Canada","volume":"17","author":"Furler","year":"2003","journal-title":"AIDS Patient Care STDs"},{"key":"10.1016\/j.cmi.2020.04.019_bib7","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1001\/archinte.158.20.2257","article-title":"Patterns of use, expenditures, and perceived efficacy of complementary and alternative therapies in HIV-infected patients","volume":"158","author":"Fairfield","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cmi.2020.04.019_bib8","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1089\/acm.2000.6.415","article-title":"Use of complementary medicine by adult patients participating in HIV\/AIDS clinical trials","volume":"6","author":"Sparber","year":"2000","journal-title":"J\u00a0Altern Complement Med"},{"key":"10.1016\/j.cmi.2020.04.019_bib9","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ctcp.2006.05.002","article-title":"Complementary and alternative medicine use in British Columbia--a survey of HIV positive people on antiretroviral therapy","volume":"12","author":"Dhalla","year":"2006","journal-title":"Complement Ther Clin Pract"},{"key":"10.1016\/j.cmi.2020.04.019_bib10","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1186\/s12906-017-1928-4","article-title":"Prevalence, patterns, and perceived value of complementary and alternative medicine among HIV patients: a descriptive study","volume":"17","author":"Bahall","year":"2017","journal-title":"BMC Complement Altern Med"},{"key":"10.1016\/j.cmi.2020.04.019_bib11","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1086\/507894","article-title":"Interactions between natural health products and antiretroviral drugs: pharmacokinetic and pharmacodynamic effects","volume":"43","author":"Lee","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2020.04.019_bib12","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1007\/s10461-017-1866-7","article-title":"Complementary and alternative medicine among persons living with HIV in the era of combined antiretroviral treatment","volume":"22","author":"Halpin","year":"2018","journal-title":"AIDS Behav"},{"key":"10.1016\/j.cmi.2020.04.019_bib13","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3389\/fpubh.2019.00179","article-title":"CAM practices and treatment adherence among key subpopulations of HIV+ Latinos receiving care in the San Diego-Tijuana Border Region: a latent class analysis","volume":"7","author":"Marks","year":"2019","journal-title":"Front Public Health"},{"key":"10.1016\/j.cmi.2020.04.019_bib14","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1089\/apc.1996.10.32","article-title":"Complementary therapy use among HIV-infected patients","volume":"10","author":"Bates","year":"1996","journal-title":"AIDS Patient Care STDs"},{"key":"10.1016\/j.cmi.2020.04.019_bib15","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ctim.2006.01.008","article-title":"Use of complementary and alternative medicine in HIV-infected subjects","volume":"14","author":"Agnoletto","year":"2006","journal-title":"Complement Ther Med"},{"key":"10.1016\/j.cmi.2020.04.019_bib16","first-page":"1057","article-title":"Prevalence and patterns of use of concomitant medications among participants in three multicenter human immunodeficiency virus type I clinical trials. AIDS Clinical Trials Group (ACTG)","volume":"7","author":"Fogelman","year":"1994","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.cmi.2020.04.019_bib17","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1345\/aph.18320","article-title":"Nonprescription and alternative medication use by individuals with HIV disease","volume":"33","author":"Smith","year":"1999","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.cmi.2020.04.019_bib18","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/00126334-200306010-00007","article-title":"Complementary and alternative medicine use and substitution for conventional therapy by HIV-infected patients","volume":"33","author":"Hsiao","year":"2003","journal-title":"J\u00a0Acquir Immune Defic Syndr 1999"},{"key":"10.1016\/j.cmi.2020.04.019_bib19","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jpainsymman.2005.05.012","article-title":"Pain and use of complementary and alternative medicine in a national sample of persons living with HIV","volume":"30","author":"Tsao","year":"2005","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.cmi.2020.04.019_bib20","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1039\/C2DT31833D","article-title":"Understanding the mechanism of cytochrome P450 3A4: recent advances and remaining problems","volume":"42","author":"Sevrioukova","year":"2013","journal-title":"Dalton Trans"},{"key":"10.1016\/j.cmi.2020.04.019_bib21","unstructured":"Role of P-Glycoprotein in Pharmacokinetics SpringerLink [Internet]. [accessed 2020 1 14]; Available from: https:\/\/link-springer-com.proxy.insermbiblio.inist.fr\/article\/10.2165%2F00003088-200342010-00003."},{"key":"10.1016\/j.cmi.2020.04.019_bib22","unstructured":"St. John\u2019s wort Drug Interactions \u2013 Drugs.com [Internet]. [accessed 2020 1 14]; Available from: https:\/\/www.drugs.com\/drug-interactions\/st-john-s-wort-index.html."},{"key":"10.1016\/j.cmi.2020.04.019_bib23","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2174\/1389200216666151103115053","article-title":"Clinically relevant pharmacokinetic herb\u2013drug interactions in antiretroviral therapy","volume":"17","author":"Fasinu","year":"2015","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.cmi.2020.04.019_bib24","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(99)05712-8","article-title":"Indinavir concentrations and St John\u2019s wort","volume":"355","author":"Piscitelli","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2020.04.019_bib25","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/00002030-200102160-00019","article-title":"Drug interaction between St John\u2019s wort and nevirapine","volume":"15","author":"de Maat","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.cmi.2020.04.019_bib26","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1086\/324351","article-title":"The effect of garlic supplements on the pharmacokinetics of saquinavir","volume":"34","author":"Piscitelli","year":"2002","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.cmi.2020.04.019_bib27","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.ejps.2010.09.016","article-title":"Garlic extract induces intestinal P-glycoprotein, but exhibits no effect on intestinal and hepatic CYP3A4 in humans","volume":"41","author":"Hajda","year":"2010","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.cmi.2020.04.019_bib28","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1248\/bpb.b16-00449","article-title":"Evaluation of the effects of S-allyl-L-cysteine, S-methyl-L-cysteine, trans-S-1-propenyl-L-cysteine, and their N-acetylated and S-oxidized metabolites on human CYP activities","volume":"39","author":"Amano","year":"2016","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.cmi.2020.04.019_bib29","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/bdd.730","article-title":"HIV protease inhibitors: garlic supplements and first-pass intestinal metabolism impact on the therapeutic efficacy","volume":"31","author":"Berginc","year":"2010","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.cmi.2020.04.019_bib30","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1097\/QAD.0b013e32835fac84","article-title":"An unusual case of HIV virologic failure during treatment with boosted atazanavir","volume":"27","author":"Duncan","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.cmi.2020.04.019_bib31","article-title":"Scientific opinion on the safety of monacolins in red yeast rice","volume":"16","author":"Younes","year":"2018","journal-title":"EFSA J"},{"key":"10.1016\/j.cmi.2020.04.019_bib32","article-title":"Prezista [Internet]","author":"Anonymous","year":"2018","journal-title":"Eur. Med. Agency"},{"key":"10.1016\/j.cmi.2020.04.019_bib33","article-title":"Norvir [Internet]","author":"Anonymous","year":"2018","journal-title":"Eur. Med. Agency"},{"key":"10.1016\/j.cmi.2020.04.019_bib34","article-title":"Reyataz [Internet]","author":"Anonymous","year":"2018","journal-title":"Eur. Med. Agency"},{"key":"10.1016\/j.cmi.2020.04.019_bib35","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/009127002237991","article-title":"Effect of Seville orange juice and grapefruit juice on indinavir pharmacokinetics","volume":"42","author":"Penzak","year":"2002","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.cmi.2020.04.019_bib36","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1046\/j.1365-2125.1998.t01-1-00687.x","article-title":"Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man","volume":"45","author":"Kupferschmidt","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cmi.2020.04.019_bib37","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1002\/ptr.4593","article-title":"Effect of grapefruit juice and ritonavir on pharmacokinetics of lopinavir in Wistar rats","volume":"26","author":"Ravi","year":"2012","journal-title":"Phytother Res PTR"},{"key":"10.1016\/j.cmi.2020.04.019_bib38","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/0140-6736(91)90872-M","article-title":"Interaction of citrus juices with felodipine and nifedipine","volume":"337","author":"Bailey","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2020.04.019_bib39","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0024-3205(02)01799-X","article-title":"The effect of grapefruit juice and seville orange juice on the pharmacokinetics of dextromethorphan: the role of gut CYP3A and P-glycoprotein","volume":"71","author":"Di Marco","year":"2002","journal-title":"Life Sci"},{"key":"10.1016\/j.cmi.2020.04.019_bib40","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1365-2125.2010.03722.x","article-title":"Fruit juice inhibition of uptake transport: a new type of food-drug interaction","volume":"70","author":"Bailey","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cmi.2020.04.019_bib41","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1067\/mcp.2002.121152","article-title":"Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine","volume":"71","author":"Dresser","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cmi.2020.04.019_bib42","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1089\/acm.2005.11.433","article-title":"Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9","volume":"11","author":"Yale","year":"2005","journal-title":"J\u00a0Altern Complement Med"},{"key":"10.1016\/j.cmi.2020.04.019_bib43","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1742-7843.2008.00227.x","article-title":"In\u00a0vitro inhibition of CYP3A4 metabolism and P-glycoprotein-mediated transport by trade herbal products","volume":"102","author":"Hellum","year":"2008","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.cmi.2020.04.019_bib44","doi-asserted-by":"crossref","first-page":"5070","DOI":"10.1128\/AAC.00672-12","article-title":"Effect of Ginkgo biloba on the pharmacokinetics of raltegravir in healthy volunteers","volume":"56","author":"Blonk","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.04.019_bib45","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1185\/030079908X260871","article-title":"Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects","volume":"24","author":"Robertson","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.cmi.2020.04.019_bib46","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1097\/QAD.0b013e32832c412b","article-title":"Interaction of Ginkgo biloba with efavirenz","volume":"23","author":"Wiegman","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.cmi.2020.04.019_bib47","first-page":"98","article-title":"A\u00a0potential drug-herbal interaction between Ginkgo biloba and efavirenz","volume":"11","author":"Naccarato","year":"2012","journal-title":"J\u00a0Int Assoc Phys AIDS Care (Chic) 2002"},{"key":"10.1016\/j.cmi.2020.04.019_bib48","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.clpt.2003.09.013","article-title":"The effect of Echinacea (Echinacea purpurea root) on cytochrome P450 activity in\u00a0vivo","volume":"75","author":"Gorski","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cmi.2020.04.019_bib49","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1592\/phco.30.8.797","article-title":"Echinacea purpurea significantly induces cytochrome P450 3A (CYP3A) but does not alter lopinavir-ritonavir exposure in healthy subjects","volume":"30","author":"Penzak","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cmi.2020.04.019_bib50","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1128\/AAC.01082-10","article-title":"Herb\u2013drug interaction between Echinacea purpurea and darunavir-ritonavir in HIV-infected patients","volume":"55","author":"Molt\u00f3","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.04.019_bib51","doi-asserted-by":"crossref","first-page":"5328","DOI":"10.1128\/AAC.01205-12","article-title":"Herb-drug interaction between Echinacea purpurea and etravirine in HIV-infected patients","volume":"56","author":"Molt\u00f3","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.04.019_bib52","article-title":"Echinaceae purpureae herba [Internet]","author":"Anonymous","year":"2018","journal-title":"Eur. Med. Agency"},{"key":"10.1016\/j.cmi.2020.04.019_bib53","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1177\/0091270011407194","article-title":"Influence of Panax ginseng on cytochrome P450 (CYP)3A and P-glycoprotein (P-gp) activity in healthy participants","volume":"52","author":"Malati","year":"2012","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.cmi.2020.04.019_bib54","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1055\/s-2007-981550","article-title":"An in\u00a0vitro Evaluation of cytochrome P450 inhibition and P-glycoprotein interaction with Goldenseal, Ginkgo biloba, grape seed, milk thistle, and ginseng extracts and their constituents","volume":"73","author":"Etheridge","year":"2007","journal-title":"Planta Med"},{"key":"10.1016\/j.cmi.2020.04.019_bib55","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1177\/0091270003253636","article-title":"Drug interaction potential of soy extract and Panax Ginseng","volume":"43","author":"Anderson","year":"2003","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.cmi.2020.04.019_bib56","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1067\/mcp.2002.126913","article-title":"Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans","volume":"72","author":"Gurley","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cmi.2020.04.019_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6882-8-50","article-title":"Pharmacokinetic and metabolic effects of American ginseng ( Panax quinquefolius ) in healthy volunteers receiving the HIV protease inhibitor indinavir","volume":"8","author":"Andrade","year":"2008","journal-title":"BMC Complement Altern Med"},{"key":"10.1016\/j.cmi.2020.04.019_bib58","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/phar.1473","article-title":"Influence of Panax ginseng on the steady state pharmacokinetic profile of lopinavir-ritonavir in healthy volunteers","volume":"34","author":"Calder\u00f3n","year":"2014","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"10.1016\/j.cmi.2020.04.019_bib59","first-page":"171","article-title":"Elevated liver enzymes resulting from an interaction between Raltegravir and Panax ginseng: a case report and brief review","volume":"27","author":"Mateo-Carrasco","year":"2012","journal-title":"Drug Metab Pers Ther"},{"key":"10.1016\/j.cmi.2020.04.019_bib60","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1124\/dmd.31.11.1391","article-title":"Human cytochrome P450 inhibition and metabolic-intermediate complex formation by Goldenseal Extract and its methylenedioxyphenyl components","volume":"31","author":"Chatterjee","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.cmi.2020.04.019_bib61","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0944-7113(00)80044-6","article-title":"An in\u00a0vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures","volume":"7","author":"Budzinski","year":"2000","journal-title":"Phytomedicine"},{"key":"10.1016\/j.cmi.2020.04.019_bib62","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.clpt.2005.01.009","article-title":"In\u00a0vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4\/5 phenotypes","volume":"77","author":"Gurley","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cmi.2020.04.019_bib63","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1177\/0091270003258660","article-title":"Influence of Goldenseal root on the pharmacokinetics of indinavir","volume":"43","author":"Sandhu","year":"2003","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.cmi.2020.04.019_bib64","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/sj.clpt.6100222","article-title":"Supplementation with Goldenseal (Hydrastis canadensis), but not Kava Kava (Piper methysticum), inhibits human CYP3A activity in\u00a0vivo","volume":"83","author":"Gurley","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cmi.2020.04.019_bib65","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1080\/03639045.2017.1342654","article-title":"Review and analysis of FDA approved drugs using lipid-based formulations","volume":"43","author":"Savla","year":"2017","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1016\/j.cmi.2020.04.019_bib66","article-title":"Aptivus [Internet]","author":"Anonymous","year":"2018","journal-title":"Eur. Med. Agency"},{"key":"10.1016\/j.cmi.2020.04.019_bib67","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1592\/phco.25.2.165.56945","article-title":"Effect of high-dose vitamin C on the steady-state pharmacokinetics of the protease inhibitor indinavir in healthy volunteers","volume":"25","author":"Slain","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cmi.2020.04.019_bib68","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1128\/AAC.05739-11","article-title":"Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir","volume":"56","author":"Song","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.04.019_bib69","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/jcph.439","article-title":"Pharmacokinetics of dolutegravir when administered with mineral supplements in healthy adult subjects","volume":"55","author":"Song","year":"2015","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.cmi.2020.04.019_bib70","article-title":"Tivicay [Internet]","author":"Anonymous","year":"2018","journal-title":"Eur. Med. Agency"},{"key":"10.1016\/j.cmi.2020.04.019_bib71","article-title":"Stribild [Internet]","author":"Anonymous","year":"2018","journal-title":"Eur. Med. Agency"},{"key":"10.1016\/j.cmi.2020.04.019_bib72","article-title":"Isentress [Internet]","author":"Anonymous","year":"2018","journal-title":"Eur. Med. Agency"},{"key":"10.1016\/j.cmi.2020.04.019_bib73","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1592\/phco.31.10.1042","article-title":"Virologic failure with a raltegravir-containing antiretroviral regimen and concomitant calcium administration","volume":"31","author":"Roberts","year":"2011","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"10.1016\/j.cmi.2020.04.019_bib74","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1128\/AAC.06407-11","article-title":"Divalent metals and pH alter raltegravir disposition in\u00a0vitro","volume":"56","author":"Moss","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.04.019_bib75","unstructured":"Drug Approval Package: BIKTARVY (bictegravir, emtricitabine, and tenofovir alafenamide) tablets [Internet]. [accessed 2019 11 8]; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/210251Orig1s000TOC.cfm."},{"key":"10.1016\/j.cmi.2020.04.019_bib76","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1093\/jac\/dkr139","article-title":"Pharmacokinetics of the HIV integrase inhibitor S\/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers","volume":"66","author":"Patel","year":"2011","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2020.04.019_bib77","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/cpdd.332","article-title":"Relative bioavailability of a dolutegravir dispersible tablet and the effects of low- and high-mineral-content water on the tablet in healthy adults","volume":"6","author":"Buchanan","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.cmi.2020.04.019_bib78","doi-asserted-by":"crossref","DOI":"10.1177\/2325958218821653","article-title":"HIV viral rebound due to a possible drug\u2013drug interaction between elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide and calcium-containing products: report of 2 cases","author":"Kang-Birken","year":"2019","journal-title":"J\u00a0Int Assoc Provid AIDS Care"},{"key":"10.1016\/j.cmi.2020.04.019_bib79","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/QAD.0000000000002438","article-title":"The effect of multivitamins and polyvalent cations on virologic suppression with integrase strand transfer inhibitors. [Letter]","volume":"34","author":"James","year":"2020","journal-title":"AIDS"},{"key":"10.1016\/j.cmi.2020.04.019_bib80","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1177\/0091270010367652","article-title":"Effect of low-, moderate-, and high-fat meals on raltegravir pharmacokinetics","volume":"51","author":"Brainard","year":"2011","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.cmi.2020.04.019_bib81","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/cpdd.358","article-title":"Single- and multiple-dose pharmacokinetics of once-daily formulations of raltegravir","volume":"7","author":"Krishna","year":"2018","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.cmi.2020.04.019_bib82","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1592\/phco.26.9.1255","article-title":"Effect of quercetin on the plasma and intracellular concentrations of saquinavir in healthy adults","volume":"26","author":"DiCenzo","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cmi.2020.04.019_bib83","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/hep.27317","article-title":"Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network","volume":"60","author":"Navarro","year":"2014","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.cmi.2020.04.019_bib84","first-page":"1760","article-title":"Changes in kidney function do not differ between healthy adults consuming higher- compared with lower- or normal-protein diets: a systematic review and meta-analysis","volume":"148","author":"Devries","year":"2018","journal-title":"J\u00a0Nutr"},{"key":"10.1016\/j.cmi.2020.04.019_bib85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/J157v04n01_01","article-title":"Effects of creatine supplementation on renal function","volume":"4","author":"Yoshizumi","year":"2004","journal-title":"J\u00a0Herb Pharmacother"},{"key":"10.1016\/j.cmi.2020.04.019_bib86","first-page":"157","article-title":"R\u00f4le de la pharmacog\u00e9n\u00e9tique dans le m\u00e9tabolisme et le transport des antir\u00e9troviraux","volume":"15","author":"Michaud","year":"2011","journal-title":"Virologie"},{"key":"10.1016\/j.cmi.2020.04.019_bib87","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0168-8278(03)00231-9","article-title":"Hepatic sinusoidal-obstruction syndrome: toxicity of pyrrolizidine alkaloids","volume":"39","author":"Chojkier","year":"2003","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cmi.2020.04.019_bib88","first-page":"215s-21s","article-title":"Identification of mechanism and pathway of the interaction between the African traditional medicine, Sutherlandia Frutescens, and the antiretroviral protease inhibitor, Atazanavir, in human subjects using population pharmacokinetic (PK) analysis","volume":"21","author":"Muller","year":"2018","journal-title":"J\u00a0Pharm Pharm Sci"},{"key":"10.1016\/j.cmi.2020.04.019_bib89","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s00228-008-0551-1","article-title":"Interaction between cat\u2019s claw and protease inhibitors atazanavir, ritonavir and saquinavir","volume":"64","author":"L\u00f3pez Galera","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.cmi.2020.04.019_bib90","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/0956462416671087","article-title":"Dietary supplement interactions with antiretrovirals: a systematic review","volume":"28","author":"Jalloh","year":"2017","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.cmi.2020.04.019_bib91","doi-asserted-by":"crossref","first-page":"289","DOI":"10.18433\/J3NG6Z","article-title":"Cranberry juice ingestion and clinical drug-drug interaction potentials; review of case studies and perspectives","volume":"16","author":"Srinivas","year":"2013","journal-title":"J\u00a0Pharm Pharm Sci"},{"key":"10.1016\/j.cmi.2020.04.019_bib92","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1592\/phco.30.8.797","article-title":"Echinacea purpurea significantly induces cytochrome P450 3A activity but does not alter lopinavir-ritonavir exposure in healthy subjects","volume":"30","author":"Penzak","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cmi.2020.04.019_bib93","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/QAD.0b013e32830261f4","article-title":"Toxic lopinavir concentrations in an HIV-1 infected patient taking herbal medications","volume":"22","author":"Beukel van den Bout-van den","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.cmi.2020.04.019_bib94","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1097\/QAD.0b013e32832c412b","article-title":"Interaction of Ginkgo biloba with efavirenz","volume":"23","author":"Wiegman","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.cmi.2020.04.019_bib95","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/phar.1473","article-title":"Influence of Panax ginseng on the steady state pharmacokinetic profile of lopinavir-ritonavir in healthy volunteers","volume":"34","author":"Calder\u00f3n","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cmi.2020.04.019_bib96","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1055\/s-0029-1186218","article-title":"Goji (Lycium barbarum and L. chinense): phytochemistry, pharmacology and safety in the perspective of traditional uses and recent popularity","volume":"76","author":"Potterat","year":"2010","journal-title":"Planta Med"},{"key":"10.1016\/j.cmi.2020.04.019_bib97","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/ptr.2750","article-title":"In\u00a0vitro inhibition of CYP3A4 by herbal remedies frequently used by cancer patients","volume":"23","author":"Engdal","year":"2009","journal-title":"Phytother Res"},{"key":"10.1016\/j.cmi.2020.04.019_bib98","doi-asserted-by":"crossref","first-page":"244","DOI":"10.2133\/dmpk.DMPK-12-RG-101","article-title":"Effects of green tea catechins on cytochrome P450 2B6, 2C8, 2C19, 2D6 and 3A activities in human liver and intestinal microsomes","volume":"28","author":"Misaka","year":"2013","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.cmi.2020.04.019_bib99","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1002\/rcm.1621","article-title":"Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography\/mass spectrometry and automated online extraction","volume":"18","author":"Unger","year":"2004","journal-title":"Rapid Commun Mass Spectrom"},{"key":"10.1016\/j.cmi.2020.04.019_bib100","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.phymed.2009.05.001","article-title":"Effects of Devil\u2019s Claw (Harpagophytum procumbens) on the multidrug transporter ABCB1\/P-glycoprotein","volume":"16","author":"Romiti","year":"2009","journal-title":"Phytomedicine"},{"key":"10.1016\/j.cmi.2020.04.019_bib101","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/2325957416680295","article-title":"Possible drug\u2013herb interaction between herbal supplement containing horsetail (Equisetum arvense) and Antiretroviral drugs: report of 2 cases","volume":"16","author":"Cordova","year":"2017","journal-title":"J\u00a0Int Assoc Provid AIDS Care"},{"key":"10.1016\/j.cmi.2020.04.019_bib102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12981-017-0140-4","article-title":"Effect of Moringa oleifera Lam. leaf powder on the pharmacokinetics of nevirapine in HIV-infected adults: a one sequence cross-over study","volume":"14","author":"Monera-Penduka","year":"2017","journal-title":"AIDS Res Ther"},{"key":"10.1016\/j.cmi.2020.04.019_bib103","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.tiv.2010.09.001","article-title":"Assessment of a dry extract from milk thistle (Silybum marianum) for interference with human liver cytochrome-P450 activities","volume":"25","author":"Doehmer","year":"2011","journal-title":"Toxicol In\u00a0Vitro"},{"key":"10.1016\/j.cmi.2020.04.019_bib104","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1177\/1091581813503887","article-title":"Inhibitory effects of spirulina platensis on carcinogen-activating cytochrome P450 isozymes and potential for drug interactions","volume":"32","author":"Savranoglu","year":"2013","journal-title":"Int J Toxicol"},{"key":"10.1016\/j.cmi.2020.04.019_bib105","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s13318-014-0180-2","article-title":"Effect of Curcuma longa on CYP2D6- and CYP3A4-mediated metabolism of dextromethorphan in human liver microsomes and healthy human subjects","volume":"40","author":"Al-Jenoobi","year":"2015","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.cmi.2020.04.019_bib106","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.tox.2007.03.007","article-title":"Inhibition of human recombinant cytochrome P450s by curcumin and curcumin decomposition products","volume":"235","author":"Appiah-Opong","year":"2007","journal-title":"Toxicology"},{"key":"10.1016\/j.cmi.2020.04.019_bib107","first-page":"265","article-title":"In\u00a0vitro activity of commercial valerian root extracts against human cytochrome P450 3A4","volume":"7","author":"Lefebvre","year":"2004","journal-title":"J\u00a0Pharm Pharm Sci"},{"key":"10.1016\/j.cmi.2020.04.019_bib108","article-title":"Viread [Internet]","author":"Anonymous","year":"2018","journal-title":"Eur. Med. Agency"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X20302275?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X20302275?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:25:51Z","timestamp":1761117951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X20302275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":108,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S1198743X20302275"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2020.04.019","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interactions between antiretroviral therapy and complementary and alternative medicine: a narrative review","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2020.04.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}